Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Schmitto, JD; Pya, Y; Zimpfer, D; Krabatsch, T; Garbade, J; Rao, V; Morshuis, M; Beyersdorf, F; Marasco, S; Sood, P; Damme, L; Netuka, I.
Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study.
Eur J Heart Fail. 2019; 21(1):90-97
Doi: 10.1002/ejhf.1284
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Zimpfer Daniel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- AIM: This study aimed to assess safety and outcomes of patients, 2 years after implantation with the HeartMate 3 Left Ventricular Assist System. METHODS AND RESULTS: This study included 50 adults with New York Heart Association (NYHA) class IIIB or IV symptoms or American College of Cardiology/American Heart Association stage D heart failure with an ejection fraction ≤25% and a cardiac index ≤2.2 L/min/m2 without inotropes, or inotrope-dependent with optimal medical management, or listed for heart transplant. The median duration of left ventricular assist device support was 694 days (range: 19-833 days). At baseline, cardiac index was 1.8 ±0.5 L/min/m2 , 58% of patients were receiving inotropes, and 92% were INTERMACS profiles 2-4. At 2 years, Kaplan-Meier survival was 74 ±6%, 5 (10%) patients were transplanted, and 32 patients (64%) remain with support. Adverse event rates include bleeding requiring surgery (16%), gastrointestinal bleeding (20%), driveline infection (24%), ischaemic stroke (16%), haemorrhagic stroke (8%), right heart failure (14%), and outflow graft thrombosis (2%). Notably, no haemolysis, pump thrombosis, or pump malfunction events occurred. At 2 years, 47% of patients remained in NYHA class I and 41% in NYHA class II (P <0.0001). From baseline to 2 years, the mean six-minute walk distance increased from 239 m to 347 m (P <0.0001), and the mean EQ-5D quality of life score improved from 48.2 to 70.6 (P < 0.0001). CONCLUSIONS: Two years post-HeartMate 3 implantation, results show expected and acceptable survival, enhanced haemocompatibility, improved patient functional status and quality of life. This corroborates the success of HeartMate 3 since its first-in-man implantation case in Germany. ClinicalTrials.gov: NCT02170363.
- Find related publications in this database (using NLM MeSH Indexing)
- Australia - epidemiology
- Canada - epidemiology
- Equipment Design - administration & dosage
- Europe - epidemiology
- Female - administration & dosage
- Follow-Up Studies - administration & dosage
- Heart Failure - mortality, physiopathology, therapy
- Heart Ventricles - physiopathology
- Heart-Assist Devices - administration & dosage
- Humans - administration & dosage
- Kazakhstan - epidemiology
- Male - administration & dosage
- Middle Aged - administration & dosage
- Prospective Studies - administration & dosage
- Stroke Volume - physiology
- Survival Rate - trends
- Time Factors - administration & dosage
- Treatment Outcome - administration & dosage
- United States - epidemiology
- Find related publications in this database (Keywords)
- HeartMate 3
- Left ventricular assist system
- Magnetic levitation
- Heart failure